Illegal Activity
none
Blackmail
none
Date
January 2018
Document Type
report
Model
gemini-2.0-flash-001
Processed
2026-02-07T18:41
Summary
This Deutsche Bank report recommends a BUY rating for DSM stock, with a target price of €100, citing Nutrition as a key growth driver and potential upside from vitamin price increases and M&A activity. The report highlights DSM's strong balance sheet and portfolio shift towards higher-value ingredients.
Metadata
- Subject
- DSM - Virginie Boucher-Ferte, BUY, close €81.8, €100 tgt, 22% potential upside
- Sender
- Deutsche Bank Gil
- Recipients
- —
- Document ID
- DB-SDNY-0086809 SDNY_GM_00232993
- Date
- January 2018
Relationships 1
| Entity 1 | Relationship | Entity 2 | Description |
|---|---|---|---|
| DSM | Business | Deutsche Bank | Deutsche Bank provides analysis and recommendations for DSM stock. |
Notable Quotes 3
We see Nutrition (68% of EBITDA) as a key growth driver.
Full exit from Materials likely, driving portfolio shift towards becoming a pure play in higher-value ingredients.
M&A should drive the next phase of development. DSM is likely to use its strong balance sheet (0.5x 17E net debt/EBITDA) to broaden its ingredients portfolio.
Financial Information
Amounts:€81.8€10030%E2016x33%15%
Assets:
- Nutrition (68% of EBITDA)
- Materials
- Ingredients
Public Knowledge
- Context
- Investment analysis reports are often of interest to media and investors.
- Media Worthy
- Yes
Raw Analysis JSON
click to expand
Themes
Financial transactions/money flowBusiness dealings
People 2
Organizations 3
DSMDeutsche BankDIPUISCI10 Bank
Locations 1
China
Financial Entities 1
Deutsche Bank
Text Analysis
- Tone
- Positive, optimistic
- Purpose
- To provide investment analysis and recommendations for DSM stock.
- Significance
- Provides insight into DSM's growth potential and financial outlook.
File Info
- File Name
- EFTA01385523.txt
- Dataset
- dataset_10
- Type
- Text
- Model
- gemini-2.0-flash-001
- Processed
- 2026-02-07T18:41:26.731809
- DOJ Source
- View on DOJ